Should I use medication or watchful waiting to treat benign prostatic hyperplasia (BPH)?
References
Citations
Roehrborn CG, McConnell JD (2007). Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. In AJ Wein, ed., Campbell-Walsh Urology, 9th ed., vol. 3, pp. 2727–2765. Philadelphia: Saunders Elsevier.
Webber R (2006). Benign prostatic hyperplasia, search date May 2005. Online version of BMJ Clinical Evidence. Also available online: http://www.clinicalevidence.com.
Presti JC, et al. (2008). Benign prostatic hyperplasia (BPH) section of Neoplasms of the prostate gland. In EA Tanagho, JW McAninch, eds., Smith’s General Urology, 17th ed., pp. 348–370. New York: McGraw-Hill.
Paterson R, Goldenberg L (2001). Benign prostatic hyperplasia. In J Teichman, ed., 20 Common Problems in Urology, part 2, pp. 185–198. New York: McGraw-Hill.
Barry MJ (2007). Benign prostatic hyperplasia. In DC Dale, DD Federman, eds., ACP Medicine, section 10, chap. 13. New York: WebMD.
Kirby R, Lepor H (2007). Evaluation and nonsurgical management of benign prostatic hyperplasia. In AJ Wein, ed., Campbell-Walsh Urology, 9th ed., vol. 3, pp. 2766–2802. Philadelphia: Saunders Elsevier.
McConnell JD, et al. (2003). The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine, 349(25): 2387–2398.
Roehrborn CG, et al. (2008). The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. Journal of Urology, 179(2): 616–621.
| Author: | Monica Rhodes | Last Updated: March 24, 2008 |
| Medical Review: | E. Gregory Thompson, MD - Internal Medicine Christopher G. Wood, MD, FACS - Urology/Oncology | |
 | ||
| |